IRTC iRhythm

BULLISH Impact: 8/10 PRESS-RELEASE
Horizon days Filed Apr 30, 2026 Processed 1mo ago Wire GlobeNewswire
Press release: earnings
Latest settled — T+20d ⚠ clustered
IRTC ▼ -9.63% at T+20d
LONG call ✗ call lost -9.63% · α vs SPY -14.91% · entry $120.80 → $109.17
Next anchor: T+60d in 7w
Last close $107.23 (close Jun 8) · -11.23% from $120.80 entry
Entry anchored
Apr 30, 03:59 PM ET
via Databento tick
T+1d
-1.34%
call -1.34% · α -1.00%
$119.18
settled 6w ago
T+5d
+3.37%
call +3.37% · α +1.02%
$124.87
settled 5w ago
T+20d
-9.63%
call -9.63% · α -14.91%
$109.17
settled 12d ago
T+60d
call — · α —
in 7w

Price Chart

Loading chart...

Executive Summary

iRhythm reported Q1 2026 revenue of $199.4M (+25.7% YoY) and GAAP EPS of -$0.43, beating consensus estimates of $194.1M and -$0.64. The company raised full-year 2026 revenue guidance to $875M-$885M and adjusted EBITDA margin to 12-13%, driven by volume growth and margin expansion across cardiology and primary care channels.

Key Financial Metrics

Guidance
$875M-$885M
raised
Free Cash Flow
-$33.1M
Gross Margin
70.9%

Actionable Insight

The strong beat and raised guidance signal accelerating volume adoption and operating leverage. Monitor upcoming 10-Q for cash flow trajectory and litigation expense trends; the stock may gap up on the guidance raise and margin inflection.

Key Facts

  • Q1 2026 revenue $199.4M vs consensus $194.1M (+2.7% beat)
  • GAAP EPS -$0.43 vs consensus -$0.64 (32.8% beat on a loss basis)
  • Revenue grew 25.7% YoY from $158.7M
  • Gross margin expanded 210 bps to 70.9%
  • Net loss improved to $13.9M from $30.7M YoY
  • Adjusted EBITDA turned positive to $14.1M from -$2.6M YoY
  • Raised FY2026 revenue guidance to $875M-$885M (prior undisclosed)
  • Raised FY2026 adjusted EBITDA margin guidance to 12-13%
  • Unrestricted cash and marketable securities $549.6M

Financial Impact

Revenue beat by ~$5.3M; EPS beat by $0.21 vs consensus; guidance raised by undisclosed amount

revenuegross marginnet lossadjusted EBITDAguidance

Risk Factors

  • Patent litigation costs ($3.7M in Q1) remain an overhang
  • Still GAAP-unprofitable with net loss of $13.9M
  • Operating cash flow negative at -$26.2M in Q1

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
90% bullish (21 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3285439
13 reports for IRTC
Performance horizon
80% Hit rate 4 of 5 directional calls best @ T+60▲ +16.97%Feb 24, 2026
Filters
Rows
Reports for IRTC — sortable, filterable
Type Now
Jun 5, 2026
4d ago
8-K
BULLISH ★ 5/10
$109.00 awaiting T+5awaiting T+5$107.23 (−1.62%)
May 28, 2026
12d ago
8-K
NEUTRAL ★ 2/10
$115.61 $107.35▼ −7.14%▼ −7.46%$107.23 (−7.25%)
May 11, 2026
29d ago
144
NEUTRAL ★ 2/10
$118.31 $110.94▼ −6.23%▼ −6.31%$107.23 (−9.37%)
May 4, 2026
5w ago
Insider Cluster
NEUTRAL ★ 2/10
$119.18 $116.84▼ −1.96%▼ −4.90%$107.23 (−10.03%)
Apr 30, 2026
5w ago
Press Release
BULLISH ★ 8/10
$120.80 $124.87▲ +3.37%▲ +1.02%$107.23 (−11.23%)
Apr 27, 2026
6w ago
Press Release
BULLISH ★ 7/10
$125.96 $119.18▼ −5.38%▼ −5.78%$107.23 (−14.87%)
Apr 17, 2026
7w ago
DEFA14A
NEUTRAL ★ 2/10
$124.91 $125.96▲ +0.84%▼ −0.07%$107.23 (−14.15%)
Feb 25, 2026
15w ago
Insider Cluster
BEARISH ★ 7/10
$135.90 $127.95▲ +5.85%▲ +4.75%$107.23 (+21.10%)
Feb 25, 2026
15w ago
Insider Cluster
BEARISH ★ 7/10
$135.90 $127.95▲ +5.85%▲ +4.75%$107.23 (+21.10%)
Feb 24, 2026
15w ago
Insider Cluster
BEARISH ★ 7/10
$137.10 $125.85▲ +8.21%▲ +7.18%$107.23 (+21.79%)
Showing 10 of 13

US Market Status

Market Closed — Opens in 8h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access